STOCK TITAN

Co-Diagnostics Announces Reverse Stock Split

(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Co-Diagnostics (CODX) filed an amendment to implement a 1-for-25 reverse stock split effective November 24, 2026. The split takes effect at 12:01 a.m. ET, and split-adjusted trading begins at the Nasdaq Capital Market open that day.

The company intends the split to maintain compliance with Nasdaq’s $1.00 minimum bid price and preserve room to issue shares for equity financing as needed. Co-Diagnostics expects approximately 521,779 common shares outstanding after the split, compared with 13,044,465 currently. The number of authorized shares will not change.

Loading...
Loading translation...

Positive

  • Minor point. Forward-looking: it has not happened yet and may not happen.Equity financing capacity is a stated aim of the split, which leaves the authorized share count unchanged

Negative

  • Minor point. Forward-looking: it has not happened yet and may not happen.1-for-25 reverse stock split is intended to maintain compliance with Nasdaq’s $1.00 minimum bid price

News Explained

Outstanding options and warrants will cover fewer shares at higher exercise prices, while fractional-share entitlements round up.

The filed amendment remains pending until November 24, 2026; when effective, outstanding options and warrants will cover fewer shares at higher exercise prices, and equity-plan share availability will also be affected.

A reverse stock split combines shares and proportionally raises the per-share price; the supplied definition says the split itself does not change company value.

Fractional-share entitlements will be rounded up to the next whole share rather than issued as fractions.

Argus 15 min delay 24 alerts
-5.95% vs previous close $0.1548 last price 1.7x rel. volume Open Argus
Details

Market Reaction – CODX

-5.8% Trough in 0 min
$0.15 – $0.20 Day Range
$1.63M Mkt Cap at Last Price

On Nov 19, the day this news came out, the latest delayed price for CODX is 5.95% below the previous close. Argus tracked a trough of -5.8% from its starting point during tracking. Our momentum scanner has recorded 24 alerts for this stock so far that day. The latest delayed price is $0.15. Relative volume is above average at 1.7x what this stock usually trades by this time of day.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Reverse split ratio: 1-for-25 Effective time: 12:01 a.m. ET on November 24, 2026 Minimum bid price requirement: $1.00 +2 more
Reverse split ratio
1-for-25
Announced reverse stock split
Effective time
12:01 a.m. ET on November 24, 2026
Reverse stock split
Minimum bid price requirement
$1.00
Nasdaq continued-listing requirement cited by the company
Common shares outstanding
13,044,465 shares
Before the reverse stock split
Expected shares outstanding
Approximately 521,779 shares
Following the reverse stock split

Previous Stock split Reports

1 past event · Latest: Dec 30
Same Type 1 event
  1. Dec 30

    Reverse stock split

    24h Move
    -21.2%

    Announced a 1-for-30 reverse split; the stock's 24-hour price reaction was -21.16%.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

reverse stock split, cusip, par value
3 terms
reverse stock split financial
"to effect a reverse stock split of its issued and outstanding common stock"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
cusip financial
"The new CUSIP number for the Company's common stock"
A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.
View in glossary
par value financial
"without effecting a change to the par value per share"
Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

SALT LAKE CITY, Nov. 19, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Diagnostics" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has filed Articles of Amendment to its Articles of Incorporation (the "Amendment") to effect a reverse stock split of its issued and outstanding common stock at a ratio of 1-for-25 shares (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 12:01 a.m. ET on Tuesday, November 24, 2026. The Company's common stock will continue to trade on The Nasdaq Capital Market under the symbol "CODX" and will begin trading on a split-adjusted basis when the market opens on Tuesday, November 24, 2026. The Reverse Stock Split is intended to enable the Company to maintain compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market, and to maintain sufficient authorized shares available for issuance to allow the Company to conduct equity financings as needed. The new CUSIP number for the Company's common stock following the Reverse Stock Split will be 189763 303.

At the Special Meeting of Stockholders held on November 13, 2026 (the "Special Meeting"), the Company's stockholders approved an amendment to the Company's Articles of Incorporation, as amended, to effect one or more reverse stock splits of the Company's issued and outstanding shares of common stock, on one or more occasions, at a ratio of not less than 1-for-2, with the cumulative effect of all such reverse stock splits not to exceed 1-for-750, such final ratio or ratios and the timing and number of any reverse stock splits to be determined by the Company's board of directors at any time within twelve months following the Special Meeting, without further approval or authorization of the stockholders. Additional information regarding the Reverse Stock Split approved by stockholders can be found in the Company's definitive proxy statement filed with the Securities and Exchange Commission (the "SEC") on October 26, 2026.

The Amendment provides that at the effective time of the Reverse Stock Split, each 25 shares of the Company's issued and outstanding common stock will be automatically combined into one (1) validly issued, fully paid and non-assessable share of common stock, without effecting a change to the par value per share. The Reverse Stock Split will impact all shares of the Company's common stock outstanding immediately prior to the effective time of the Reverse Stock Split, as well as the number of shares of common stock available for issuance under the Company's equity incentive plans. In addition, the Reverse Stock Split will effect a reduction in the number of shares of common stock issuable upon the exercise of stock options and warrants outstanding immediately prior to the effectiveness of the Reverse Stock Split with a corresponding increase in the applicable exercise price per share, in each case in accordance with the terms thereof. The Reverse Stock Split will not change the number of shares of capital stock authorized for issuance under our Articles of Incorporation. Based on the 13,044,465 shares of common stock currently outstanding, we expect approximately 521,779 shares of common stock to be issued and outstanding following the Reverse Stock Split.

No fractional shares will be issued in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to receive fractional shares as a result of the Reverse Stock Split will have those shares rounded up to the next whole share. Stockholders with shares in brokerage accounts should direct any questions concerning the reverse stock split to their broker; all other stockholders may direct questions to the Company's transfer agent, VStock Transfer, LLC.

About Co-Diagnostics, Inc.:

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA") that are subject to a number of risks and uncertainties. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. There can be no assurance that implementing a reverse stock split will result in the Company maintaining compliance with Nasdaq listing requirements or that the Company will be able to conduct equity financings in the future. A discussion of additional risks and uncertainties can be found in the Company's Risk Factors disclosure in its Annual Report on Form 10-K, filed with the SEC on March 31, 2026, and in the Company's other filings with the SEC, including Quarterly Reports on Form 10-Q. Co-Diagnostics undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this press release.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-announces-reverse-stock-split-302946143.html

SOURCE Co-Diagnostics

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does the Co-Diagnostics (CODX) reverse stock split take effect, and what is the ratio?

The 1-for-25 reverse stock split takes effect at 12:01 a.m. ET on November 24, 2026. CODX begins trading on a split-adjusted basis when the Nasdaq Capital Market opens that day.

How will Co-Diagnostics handle fractional shares in the CODX reverse stock split?

Co-Diagnostics will round fractional entitlements up to the next whole share rather than issue fractional shares.

How will the Co-Diagnostics reverse stock split affect outstanding stock options and warrants?

Outstanding stock options and warrants will cover fewer common shares at a correspondingly higher exercise price per share, in line with their terms.

Can Co-Diagnostics implement another reverse stock split without a new shareholder vote?

Shareholders authorized the board to implement one or more reverse stock splits without another shareholder vote within twelve months after the November 13, 2026 special meeting. The authorization sets a minimum ratio of 1-for-2 and caps the cumulative effect at 1-for-750.

Keep reading